Abstract:Objectives: This study aims to demonstrate the role of case-level American College of Medical Genetics (ACMG) criteria, such as familial segregation and pathology data, in providing conclusive evidence for the pathogenicity of ultrarare GLA variants causing Anderson-Fabry disease when gene-level and variant-level criteria provide ambiguous or discrepant results. Case/family description: A 52-year-old woman presented with new-onset shortness of breath, chest pain, and palpitations. Echocardiography revealed mild left ventricular wall thickening (14 mm) and mild diastolic dysfunction. She was the second of three siblings born to unrelated parents, both of whom died from malignancies. Family screening identified brothers, one affected 55-year-old with hypertension and asthma and one unaffected 47-year-old. The 15-year-old son of the proband complained of exercise-induced burning feet acral pain his electrocardiogram showed a short PR interval and signs of early hypertrophy. Results: Endomyocardial biopsies of the proband and the affected sibling demonstrated substrate accumulation (globotriaosylceramide). The anti-α-galactosidase-A immunostain showed a total loss of the enzyme in the hemizygous male and a mosaic pattern in the heterozygous female. The next-generation sequencing short-read multigene panel identified the c.547+3A>G variant in the GLA gene and excluded variants in other genes; Oxford-Nanopore long-read sequencing excluded known pathogenic deep intronic variants. A Multiplex-Ligation-dependent-Probe-Amplification assay excluded copy number variations. Based on the variant-level and gene-level ACMG criteria, the variant was classified as a Variant of Uncertain Significance or Likely Benign using different bioinformatic tools. By adding case-level functional data (endomyocardial biopsy, PS3_VeryStrong) and familial data (segregation of genotype with phenotype, PP2_Moderate), the variant was classified as Likely Pathogenic/Pathogenic. Conclusion: ACMG case-level data can unambiguously resolve uncertain interpretations of GLA variants.

Previously Unidentified Gene Variation Associated with Fabry Disease: The Impact on One Family

Identification of a novel nonsense mutation in α-galactosidase A that causes Fabry disease in a Chinese family

Identification of a Missense Mutation in the α-galactosidase A Gene in a Chinese Family with Fabry Disease

[Pedigree Investigation of Clinicopathologic Features and Alpha-Galactosidase A Gene Mutation in a Family with Fabry Disease].

c.640–814 T > C mutation in deep intronic region of alpha-galactosidase A gene is associated with Fabry disease via dominant-negative effect

Functional evaluation of a novel GLA causative mutation in Fabry disease.

Genetic and Clinical Study of Three Chinese Pedigrees with Fabry Disease

Novel α-galactosidase A gene mutation in a Chinese Fabry disease family: A case report

Identification and Functional Characterization of the First Deep Intronic GLA Mutation (IVS4+1326C>T) Causing Renal Variant of Fabry Disease

GLA Variation P.e66q Identified As the Genetic Etiology of Fabry Disease Using Exome Sequencing.

A Novel Α-Galactosidase A Splicing Mutation Predisposes to Fabry Disease

Unambiguous Interpretation of the Pathogenicity of the GLA c.547+3A>G Variant Causing Fabry Disease

Novel GLA gene mutations in two Chinese families with classic Fabry disease

Fabry Disease with Genetic Variants of Unknown Significance and Concomitant Immunoglobulin A Nephropathy

[Two Novel Mutations of GLA Gene in Chinese Patients with Fabry Disease].

Fabry Disease: Renal Biopsy-Proven Cases from China

Mild Left Ventricular Hypertrophy Unravels a Novel Nonsense Mutation of the GLA Gene Associated with the Classical Phenotype of Fabry Disease

Functional and Biological Studies of Alpha-Galactosidase A Variants with Uncertain Significance from Newborn Screening in Taiwan

No evidence of Fabry disease in a patient with the new p.Met70Val GLA gene variant

Same genotype and different phenotypes in a Fabry disease family

GLA Mutations Suppress Autophagy and Stimulate Lysosome Generation in Fabry Disease